Top > Search of International Patents > PREVENTIVE AGENT AND THERAPEUTIC AGENT FOR CATARACTS, AND USE OF HAT INHIBITOR FOR PRODUCTION THEREOF

PREVENTIVE AGENT AND THERAPEUTIC AGENT FOR CATARACTS, AND USE OF HAT INHIBITOR FOR PRODUCTION THEREOF

Foreign code F180009454
File No. (FU684)
Posted date Jul 25, 2018
Country WIPO
International application number 2017JP034204
International publication number WO 2018079149
Date of international filing Sep 22, 2017
Date of international publication May 3, 2018
Priority data
  • P2016-208121 (Oct 24, 2016) JP
  • 2017JP19034 (May 22, 2017) WO
Title PREVENTIVE AGENT AND THERAPEUTIC AGENT FOR CATARACTS, AND USE OF HAT INHIBITOR FOR PRODUCTION THEREOF
Abstract Provided are: a novel preventive agent and a novel therapeutic agent for cataracts; and use of an HAT inhibitor for production thereof. The preventive agent or therapeutic agent for cataracts according to the present invention contains an HAT inhibitor as an active ingredient.
Outline of related art and contending technology BACKGROUND ART
A cataract, by embedded in the quartz body, a disease may cause loss of vision. Depending on the type of cataract, was in the crystalline lens, nuclear, cortical or after pouch becomes clouded. Is a type of cataract, cataract aging, diabetes cataract and the like are present. Among these affected by cataract is the greatest age, increasing the rate of finding that with age, and may also include an initial opacity, Japan have the cost of finding rate 66-85% is 60 years, 70 years without the cost of finding rate 84-97%, 100% to 80 years of age or older is reached. On the other hand, the age of 60 suffering from diabetes cataracts are many users who, the youth may also develop a disease.
To the treatment of cataracts, after occurrence of haze in the main treatment by surgery, administration of prophylactic or therapeutic agent has also been performed. Preventing or suppressing progression of the above as an example, non-patent document 1 glutathione, non-patent document 2 is reported pirenoxine.
Scope of claims (In Japanese)[請求項1]
HAT阻害剤を有効成分として含有している、白内障の予防剤または治療剤。
[請求項2]
上記HAT阻害剤は、HAT1、NAA60、GCN5、PCAF、TIP60、MOZ、MORF、HBO1、MOF、P300、CBP、TAF1、TIFIIIC90、SRC1、SCR3、P600、CLOCKおよびNAT10からなる群より選択される1種以上の物質を標的とするものである、請求項1に記載の白内障の予防剤または治療剤。
[請求項3]
上記HAT阻害剤は、ポリフェノール由来の化合物、構造中にヘテロ環を含んでいる化合物、安息香酸誘導体、またはα-β不飽和カルボニル化合物である、請求項1または2に記載の白内障の予防剤または治療剤。
[請求項4]
上記HAT阻害剤は、2,6-ビス((e)-3-ブロモ-4-ヒドロキシベンジリデン)シクロヘキサン、CTK7A、Epigenetic Multiple Ligand、MG149、C646、NU9056、CPTH2、5-クロロ-2-(4-ニトロフェニル)-3(2H)-イソチアゾロン、ブチロラクトン3、EML425、L002、ISOX DUAL、TH1834、SPV106、Windorphen、ケトミン、Remodelin、エンベリン、Ischemin、CBP30およびKG501からなる群より選択される1種以上の物質、または当該物質の誘導体もしくは塩である、請求項1または2に記載の白内障の予防剤または治療剤。
[請求項5]
投与剤型が点眼剤である、請求項1~4の何れか1項に記載の白内障の予防剤または治療剤。
[請求項6]
上記白内障は、糖尿病白内障である、請求項1~5の何れか1項に記載の白内障の予防剤または治療剤。
[請求項7]
白内障の予防剤または治療剤を製造するための、HAT阻害剤の使用。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • UNIVERSITY OF FUKUI
  • Inventor
  • OKI, Masaya
  • KANADA, Fumito
  • TAKAMURA, Yoshihiro
  • MIYAKE, Seiji
  • UCHIDA, Hiroyuki
IPC(International Patent Classification)
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close